Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma. Issue 1 (2nd January 2018)

• Record Type: Journal Article
• Authors: Milone, Giuseppe; Martino, Massimo; Leotta, Salvatore; Spadaro, Andrea; Zammit, Valentina; Cupri, Alessandra; Avola, Giuseppe; Camuglia, Maria Grazia; Di Marco, Annalia; Scalzulli, Potito; Morelli, Mara; Olivieri, Attilio; Tripepi, Giovanni
• Is Part Of: Leukemia & lymphoma. Volume 59:Issue 1(2018)
• Page Start: 42
• Page End: 48
• Publication Date: 2018-01-02
• Subjects: Plerixafor -- CD34+ mobilization -- PBSC aphaeretic harvest; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2017.1324161
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: We here report final results of a phase II/III prospective study that evaluated in Multiple Myeloma the use of on-demand plerixafor (PLX) added to mobilizing chemotherapy for patients showing predictive signs of mobilization failure. A total of 111 patients with MM were registered, all received cyclophosphamide 4 g/m 2 and granulocyte colony-stimulating factor (G-CSF). Overall, a successful CD34+ cell mobilization was achieved in 97.2% (108/111) of patients. Minimum harvest (≥2.0 × 10 6 CD34+ cells/kg) was achieved in 97.2% (108/111) and optimal harvest success (≥4.0 × 10 6 CD34+ cells/kg) was achieved in 84.6% (94/111). Multivariate analysis showed that patients who received on-demand PLX treatment had significantly higher likelihoods of successfully achieving both the minimal ( p = .006) and optimal harvest ( p = .05) in respect to a historical control group mobilized without any PLX. The incremental cost-effectiveness ratio, for each 1% increase in probability of achieving a successful minimal harvest, was€ 40.6 per patient.